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Summary 
The management and needs of people with intellectual disability (ID) and epilepsy are 
well evidenced; less so, the comorbidity of behavioural disorder in this population.  
‘Behavioural disorder’ is defined as behaviours that are difficult or disruptive, including 
stereotypes, difficult or disruptive behaviour, aggressive behaviour toward other people, 
behaviours that lead to injury to self or others, and destruction of property. These have an 
important link to emotional disturbance. This report, produced by the Intellectual Disability 
Task Force of the Neuropsychiatric Commission of the ILAE, aims to provide a brief review 
of some key areas of concern regarding behavioural disorder among this population, and 
proposes a range of research and clinical practice recommendations generated by Task Force 
members.  The areas covered in this report were identified by experts in the field as being of 
specific relevance to the broad epilepsy community when considering behavioural disorder in 
persons with epilepsy and ID; they are not intended to be exhaustive. The practice 
recommendations are based on the authors’ review of the limited research in this field 
combined with their experience supporting this population. These points are not graded but 
can be seen as expert opinion guiding future research and clinical practice. 
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Epidemiology 
ID is typically diagnosed when individuals are assessed as having limitations in both 
intellectual functioning (an IQ of 70 or under) and adaptive behaviours (conceptual, practical 
and social skills) with onset occurring during the developmental period1. Approximately 
1.04% of the population are estimated to have intellectual disability2. Challenges arise 
however in determining prevalence estimates for this population as they typically rely on 
persons known to specialist service providers and therefore may exclude a ‘hidden’ 
population who do not engage with services, likely those with mild ID. 
The prevalence of epilepsy among individuals with ID has been found to be well in 
excess of that reported in the general population; at 22% (CI95% 19.6-25.1) in a pooled 
estimate determined from a recent meta-analysis of 48 studies published since 19903. 
Prevalence estimates for the general population, in contrast, are considerably lower (0.80%) 4. 
Early studies examining the prevalence of behavioural disorder among this population 
reported elevated levels among children with ID and epilepsy5.  Molteno et al (2001)6, in a 
study of 355 children attending special schools in South Africa, reported higher levels of 
psychopathology among those who had epilepsy, notably in the domains of self-absorbed and 
autistic related behaviours. Similarly, McGrother et al (2006)7, in a large sample of 2,393 
adults with ID, found that those with epilepsy were more likely than those without epilepsy to 
engage in disturbing others at night, seeking attention (16.1% vs. 10.6%), and being 
uncooperative (20.0% vs. 12.6%). In contrast to these findings, Robertson et al (2015)3 
identify a number of studies which report no difference in rates of behavioural problems 
between individuals with intellectual disability who have epilepsy and those who do not. 
A small number of studies have reported a decreased rate of behavioural disorder 
among persons with epilepsy and ID. A population-based prevalence study of 416 individuals 
with severe and profound ID in Finland reported a higher percentage of individuals without 
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epilepsy presenting with behavioural disturbance (27.9% vs 17.6%)8. Similarly, Arshad et al 
(2011)9 found that rates of mental health problems were significantly lower among 
participants with epilepsy (9.4%) than participants without epilepsy (48.2%) in a sample of 
752 individuals with ID who were consecutive referrals for assessment to a specialist mental 
health service. Specifically, rates for schizophrenia (7.1% vs. 20.3%), personality disorder 
(3.8% vs. 8.6%), and anxiety (4.5% vs. 7.9%) were significantly lower among those with 
epilepsy. 
While the evidence base is limited, these studies suggest a complex relationship 
among ID, epilepsy and behavioural disorder. It is likely that methodological differences in 
samples, case definitions, and diagnostic criteria impact the variation in findings. A reduction 
in these differences towards more standardised methodologies may contribute to a greater 
understanding of the combined impact of these complex conditions. 
Practice points for epidemiology 
1.  Population-based epidemiological studies are recommended to ensure that individuals at 
all levels of intellectual disability are represented.  
2. Standardised definitions of intellectual disability, epilepsy and behavioural disorder should 
be agreed upon to ensure consistency among epidemiological studies. 
 
Aetiology 
Current evidence suggests a number of key variables may influence the likelihood of 
behavioural disorder for individuals with ID and epilepsy: genetic causation, severity of ID, 
and the presence of autistic spectrum characteristics.  Powis and Oliver10 for example, 
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reviewing the prevalence of aggression in a range of genetic disorders, noted that certain 
conditions appear to have greater prevalence of aggression as compared with others. 
The environment has also been identified as impacting the development and 
maintenance of behavioural problems. Environmental factors may have specific impact for 
known genetic syndromes and often the impact leads to the phenotypic behaviours11. 
Exposure to life events, for example, increases the risk of psychopathology while 
environmental responses, such as reinforcement and punishment, may act as maintaining 
factors of these behaviours12. 
When considering epilepsy variables in the aetiology of behavioural disorder, the role 
of factors such as seizure frequency, peri-ictal events and antiepileptic drugs (AEDs) have 
been examined. The impact of AEDs is covered later in this report. Psychiatric phenomena in 
the peri-ictal period, in particular post-ictal psychosis, are well described (see for example 
Clancy et al, 201413) and an association with violent acts has been observed. In the general 
epilepsy population, both post-ictal confusional states and rage have been documented14. 
Such behaviours may reflect alterations in cortical excitability15.  Considerable challenges 
remain for clinicians to determine the source of behavioural disorder, whether due to 
epilepsy, use of medication, a combination of both or other factors16.  
Practice points for aetiology 
1.  Assessment of the aetiology of behavioural disorder should include identification of the 
cause of an individual’s ID. 
2.  The presence of autistic traits should be identified in any individual presenting with 
behavioural disorder. 
3. Assessment of challenging behaviour should include an assessment for comorbid 
psychopathology such as ADHD.  
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4.  In all individuals the association between seizures and peri-ictal behavioural changes 
should be identified. 
5.  In all individuals the association between seizure worsening or improvement and 
behaviour change should be assessed. 
 
Behavioural side effects of antiepileptic drugs 
There is a dearth of high quality information on behavioural changes associated with 
AED use among individuals with epilepsy and ID. A Cochrane Review found that the 
majority of studies in this field typically used no or non-reliable measures of behavioural 
exacerbation, were uncontrolled, and were mostly retrospective in nature17. 
The impact of AEDs on behaviour and cognition ranks second within 11 areas 
prioritized in consensus guidelines developed by the Health Special Interest Group of 
IASSIDD (International Association for the Scientific Study of Intellectual and 
Developmental Disability)17. Whilst newer AEDs in general offer some advantages as 
compared to older AEDs, mainly a lack of enzyme-inducing properties, they may also result 
in behavioural side effects.  
Access to AEDs will be restricted in many countries globally; the restriction being a 
lack of more modern AEDs. It is important to recognise that some medications that are rarely 
used because of behaviour concern (an example of which could be phenobarbitone) may be 
used frequently in countries with low income and limited availability of AEDs. This may lead 
to an increase in behavioural effects. 
Research indicates that some AEDs may have both positive and negative behavioural 
side effects.  Helmstaedter and colleagues, for example, reported that 59% of 228 consecutive 
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out-patients prescribed levetiracetam reported behavioural changes compared to 9% of 
controls; of these 37% reported negative changes in behaviour and 22% positive changes19. 
These side effects may also occur in persons with ID, in some cases to a higher frequency 
than that observed for the general epilepsy population specifically, for those prescribed 
levetiracetam, aggressive behaviour has been reported to occur more frequently in persons 
with ID19. 
Research assessing lamotrigine, though generally believed to have a positive impact 
on behaviour, has reported negative changes. Seven out of 20 individuals with ID (five with 
Lennox Gastaut syndrome) who were prescribed lamotrigine as part of different AED 
regimens spontaneously reported behavioural changes using the Aberrant Behaviour 
Checklist (ABC) 20. Behavioural improvement was observed for four individuals, whilst 
adverse behavioural effects were noted for three; findings which the authors state reflect the 
varied influence of lamotrigine on behaviour. The authors also note that serum concentrations 
of lamotrigine were not predictive of behavioural change. 
A randomized, double-blind, placebo-controlled trial of topiramate reported improved 
behaviour in both active and control groups with no statistical difference between the 
groups21. In contrast, an open prospective study showed significant adverse cognitive and 
behavioural side effects of topiramate in children and adolescents with ID22. More recently, 
an evaluation of routine clinical data reported that individuals with epilepsy and ID may 
experience the same cognitive side effects under topiramate as individuals who do not have 
ID23. 
Behavioural improvement for those prescribed vigabatrin was associated with seizure 
freedom in seven children with epileptic, formerly infantile, spasms24. The positive impact of 
seizure improvement is likely to be true across AEDs but has not been researched. Other 
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AEDs that are associated with such behavioural side effects in persons without ID, for 
instance zonisamide or perampanel, can cause these effects in persons with ID, although no 
clinical trial data specific to people with ID and epilepsy exist. High drug load may also be 
associated with negative behavioural changes and is frequent in persons with epilepsy and 
ID25. Older AEDs (e.g. primidone and phenobarbital) may also have behavioural side effects, 
including when drug withdrawal is tried. 
In summary, the impact of AEDs on behavioural change is, in many cases, 
unpredictable due to a lack of trial information. To address this issue, clinicians are 
encouraged to monitor behavioural change closely, employing established instruments for the 
assessment of adverse events such as the Adverse Event Profile (AEP) 26 or the FENAT27. 
Similarly, the ABC is a widely-used instrument assessing behaviour profiles in persons with 
ID28 and could be considered in clinical practice. 
 
Practice points for behavioural side-effects of anti-epileptic drugs 
1.  AEDs may have positive or negative behavioural side effects in persons with ID. 
2.  Behavioural effects should be monitored closely. 
3.  Validated assessment scales are needed for patients with epilepsy and ID. 
4.  There is a major need for research into behavioural safety of AEDs in persons with ID. 
 
 
Pharmacological treatments of behavioural disorder 
Multiple difficulties hinder efforts to include people with ID in randomised controlled 
trials (RCTs). These difficulties include, amongst others: consent, difficulty in applying 
strictly controlled protocols, heterogeneity of aetiology, and blurred boundaries between 
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target symptoms. Consequently, data reliably proving or disproving the effectiveness of 
specific psychotropic agents are lacking, especially among those with co-morbid epilepsy. 
Table one summarises current clinical recommendations for the use of psychotropic 
medication for aggression. 
[Insert Table 1 here] 
 
The lack of clinical trial information, compounded by evidence of the impact of 
antipsychotics on seizure frequency leads to considerable clinical equipoise39. For the 
clinician in epilepsy it should be considered that no drug is often the best drug for this group 
of patients. When medication is used, it should be originated from services competent in 
ongoing assessment of the behaviour, the environment and other associated psychopathology. 
 
Practice points for pharmacological treatments of behavioural disorder 
1.  Behavioural disorder is multifactorial and a thorough assessment, including a functional 
analysis of behavior, is needed before medication is started. 
2.  Use of medications to manage behaviour is not recommended for non-experienced 
epilepsy services; shared care with psychiatric services is needed. 
3.  When used, courses should be short and monitored for efficacy. 
4.  Psychotropic medication can be used to treat mental illness contributing to behaviours that 
are challenging. 
 
Epilepsy surgery and the risk of cognitive or behavioural change 
The European Federation of Neurological Sciences (EFNS) and the Epilepsy Surgery 
Guidelines and Proposed ILAE Criteria for Epilepsy Surgery in Children do not consider ID 
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as a contraindication to proceed with a surgical procedure40-41. Moreover in the UK, National 
Institute for Health and Care Excellence (NICE) Guidelines state that children, young people 
and adults with ID must not be discriminated; therapies and investigations for the general 
epilepsy population should be offered42. The number of patients with a low IQ that are 
offered surgery, however, remains less than those functioning within the normal intelligence 
range43. 
 
Limited information on the behavioural outcome of surgery exists to help in decision 
making. An analysis of 664 patients found no association between seizure outcome, 
postoperative cognitive development and behavioural outcome (using the Child Behaviour 
Checklist) and IQ level (≤ 70, 70-85, >85) when patients were matched according to surgical 
variables such as age or surgical procedure44. Behavioural outcome showed lower scores one 
year after surgery in all groups, indicating fewer behavioural difficulties after surgery than 
before. Other factors, such as duration of epilepsy, were also associated with seizure outcome 
in patients with a low IQ45. 
No deterioration of cognitive functioning was observed in patients with a low IQ 
compared to those functioning within the normal intelligence range44. A further study of a 
series of 31 patients evaluated with the Washington Psychosocial Seizure Inventory showed 
an improvement in psychosocial functioning for those who became seizure free45. 
Liang et al, described low IQ as a factor associated with cognitive improvement in a 
small series of 25 patients with tuberous sclerosis complex (TSC) who underwent epilepsy 
surgery46. Another review paper identified the benefits of epilepsy surgery in 177 patients 
with tuberous sclerosis, where IQ was reported in 62 cases (50 patients with ID); the authors 
concluded that deterioration of cognitive functioning may be prevented with epilepsy 
surgery47. 
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A predominance of large surgical resections (multilobar, hemispherectomy) was 
observed in patients with lower IQ48.Other palliative procedures like corpus callosotomy 
(CC) and vagal nerve stimulators, have also been extensively used in this population. 
Although postsurgical cognitive complications like disconnection syndrome have been 
reported more frequently in patients after CC, a recent paper found that after this procedure, 
half of patients showed attention enhancement (related to improvement in drop attacks) and 
behavioral outcome was better at earlier age of surgery49. 
 
Practice points for epilepsy surgery and ID 
1. ID is not a contraindication for epilepsy surgery and a presurgical evaluation should be 
offered in refractory cases as in other patients with epilepsy. 
2. Epilepsy surgery can benefit cognitive and behavioural outcomes especially in patients 
who remain seizure free. 
3. Patients and families should be advised that although current data is positive, the precise 
impact of surgery on an individual’s epilepsy, and indeed their intellectual functioning, 
cannot be fully predicted. 
 
Psychological management of behavioural &emotional issues 
Psychological therapies and behavioural management techniques are effective in 
improving the quality of life of people with ID50-51. Despite this, there is limited research 
investigating cognitive or behavioural treatments, and currently, there are no randomised 
controlled trials assessing the efficacy of psychological therapies in persons with comorbid 
ID and epilepsy52. This is concerning given the range of psychosocial challenges facing 
individuals with ID, including unemployment and poverty, a lack of meaningful friendships 
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or intimate relationships, stressful family circumstances, trauma and abuse, and elevated rates 
of mental health difficulties51.  Moreover, for persons with ID and epilepsy, there is limited 
information on the long-term effects of seizures on their cognitive and behavioural 
functioning, and they face the added psychosocial challenges of living with often ‘hard to 
treat’ epilepsy, including reduced daily living skills, self-care and adaptive social behaviours, 
social stigma, lack of independence, exploitation by others, and increased carer burden and 
burnout53. 
There appears to be a barrier to referral for treatment; adults with ID are less likely to be 
referred for psychological therapy than adults without ID50. Also relevant is poor detection of 
mental health problems associated with: (i) ‘diagnostic overshadowing’, where a mental 
health problem is not recognised due to difficulties differentiating it from challenging 
behaviours associated with ID51, (ii) the lack of diagnostic assessment tools with robust 
evidence of reliability and validity for detecting mental health problems, and (iii) the 
treatment gap between mental health and ID services, which have distinct cultures, and can 
be detrimental to identifying problems and providing continuity of care51. 
In considering the cognitive abilities necessary for psychological therapy in people with 
ID, the success of cognitive behaviour therapy (CBT) in children without ID highlights that 
fully developed adult abilities are not needed to gain treatment benefits. Despite this, the 
cognitive content of treatment (i.e., what a person thinks) has generally been overlooked in 
favour of the cognitive process (i.e., how a person thinks), even though the former can 
underpin an individual’s psychosocial difficulties and can be targeted in treatment51. 
A cognitive deficit model has been commonly used with people with ID, which promotes 
increased self-monitoring through instructional training, often in the form of a behaviour 
modification program, to ameliorate cognitive and behavioural difficulties. This contrasts 
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with the cognitive distortion model of CBT traditionally employed with adults without ID, 
where the therapist elicits negative automatic thoughts, identifies the relevant cognitive 
distortions, and helps the individual to modify or reframe thinking to improve mood and 
wellbeing. Since the latter has been shown to have better generalisability across behaviours 
and environmental settings, ideally both models should be considered when referring people 
with ID and epilepsy for treatment51,54. 
A ‘step-wise’ approach to psychological treatment in patients with ID is recommended, 
whereby patients should first undergo formal neuropsychological assessment of their 
cognitive abilities and skills prior to commencing treatment to identify cognitive strengths 
and weaknesses54. Since over 80% of people with ID have mild ID, neuropsychological 
testing can profile the patient’s general intellect (IQ), memory, attention, information 
processing speed, verbal communication and comprehension, and executive functions (i.e., 
planning, abstract reasoning, mental flexibility, working memory), with higher verbal IQ 
linked to better treatment outcomes in some studies51-54. Also beneficial is an assessment of 
the patient’s metacognitive profile, particularly relating to emotional recognition, self-
awareness, insight, and an ability to understand the links between cognition and emotion, as 
these skills are directly relevant to the success of CBT54. 
Following the initial assessment, the therapist can then build on existing patient skills 
and work to develop new skills where required to maximise the effectiveness of the 
intervention. Where abilities or skills are unable to be developed, the intervention should be 
adapted51, 54 with the goal of enhancing communication and understanding of the patient 
experience so that a shared understanding between the patient, carer and therapist can be 
achieved55. Examples of ways in which psychological therapy can be tailored to the cognitive 
abilities and skills of the patient are provided in Table 256-57. 
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[Insert Table 2 here] 
Table 3 contains a summary of psychological treatment studies of mental health 
problems in individuals with ID using a cognitive behaviour approach. Across studies, the 
strongest evidence supports the efficacy of CBT in treating aggression and anger in people 
with ID58. Anger is a challenging emotion to treat in adults both with and without ID, and has 
clinical salience in the ID population as aggression can lead to institutionalisation and over-
prescription of medications for behavioural control. Moreover, resolving anger can remove 
attentional biases and cognitive distortions associated with threat perception, as well as 
memory biases for distressing experiences that are challenging to process58.  Thus, the use of 
CBT for the effective treatment of anger and aggression in people with ID speaks to the 
viability of cognitively-based psychological treatments for improving patient quality of life. 
[Insert Table 3 here] 
 
Practice points for Psychological management of behavioural &emotional issues  
1. People with ID should not be excluded from psychological therapies but should be able to 
access psychological therapies when needed. 
2. A ‘step-wise’ approach is recommended, including neuropsychological assessment of 
cognitive strengths and weaknesses and subsequent tailoring of the therapy to build on 
existing patient skills. 
3. Both behaviour modification and CBT should be considered, and for persons with mild ID 
who present with anger, psychological therapies such as CBT may be beneficial. 
4. Clinicians should also consider treatment of comorbid mental illness in people with ID 
with behavioural challenges. 
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Challenges in adolescence: autism, behaviour and epilepsy. 
Up to 33% of people with epilepsy of childhood-onset have persistence of seizures 
into adulthood, and 19-35% never achieve remission61,62 Whilst this non-remission group 
often have associated neurodeficits, unless severely affected, most will survive into 
adulthood63. With age, complications are common affecting cognitive, behavioural and 
psychosocial functioning. 
Tuberous Sclerosis Complex offers a useful model for the transition of children with 
epilepsy, behaviour and developmental disability. People with TSC have ID in 50% of cases, 
which may be severe, and 40% have Autism Spectrum Disorder (ASD). As the child grows 
into adulthood the emphasis of care shifts from seizure control and developmental issues to 
renal, psychiatric disease and other issues64. Remission of epilepsy occurs for many patients 
permitting AEDs to be tapered off65.  In patients with TSC the severity and phenotype of the 
autistic features are inextricably linked with intelligence and epilepsy outcomes. Mental 
health issues occur in 66% of individuals with TSC, with anxiety and obsessive-compulsive 
tendencies common and handicapping. 
Transition to adult services is complex as there are many medical issues which change 
with age and fall outside the neurological system66. Hence a “medical team” is needed. 
Effective transition programs from paediatric to adult care need both services to work 
together. Support for family and carers must be in place including identification of 
guardianship, establishment of trust funds, exploration of residential living options, preparing 
for changes in the family such as parental aging, carers having their own medical issues, and 
addressing the parental concerns of what will happen to the child who outlives them64. 
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Adult epilepsy or neurology waiting rooms and clinics are ill-equipped for younger 
patients who present with behavioural difficulties, and adult neurologists can be 
uncomfortable with such patients, especially those with aggressive behaviour, sexuality 
expression, and sleep disorders67. 
Input from a pharmacologist is needed since there is often polypharmacy not just 
related to AEDs67. Involvement of other medical and non-physician services should include 
primary care for basic health maintenance such as nutrition, influenza immunization, and 
dentistry67,68. Also input from speciality physicians and rehabilitation therapists are 
needed68,69. 
It is important to plan early for transition, to identify on-going caregivers and decide 
which is better, an actual isolated once off “hand-over” clinic or a chronic combined service. 
The clinician must be aware that other health issues may dominate such as behavioural 
disorders, and psychiatric manifestations. The social challenges can be huge and it may be 
better for a non-neurologist to lead the chronic on-going care plan. It is important to work as 
a flexible team. 
In order for the above to be effective it is essential for the child neurologist to prepare 
and plan ahead, and to identify and involve key role players. 
 
Practice points for challenges in adolescence: autism, behaviour and epilepsy 
1. Transition of patients with complex disability should be planned. 
2. The adult service will need to reproduce an often comprehensive paediatric model of care 
including physical, cognitive, psychiatric and behavioural needs. 
3. The presence of ASD should be noted. 
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4. Individual aetiology of the ID is crucial and allows prospective care planning. 
5. Adult services should be identified prior to transition. 
 
 
Social Policy - supporting family caregivers of those with complex disability 
Families are distinguished as both recipients and contributors to the care and support 
of individuals who have ID and epilepsy.  The evidence-base, while limited, suggests a level 
of dissatisfaction by families in both roles. 
As recipients of services, families report challenges sourcing specialist expertise, 
notably at primary care level; consultations characterised by poor communication and 
insufficient time; professionals lowering their expectation of treatment options for this 
population; and reluctance by some professionals to provide support regarding behavioural 
problems70. Moreover, interagency collaboration amongst these professionals is poor, 
resulting in families navigating a complex and fragmented pathway to care71. 
While professional services are challenged in supporting individuals with such 
complex needs72, it is families that carry most of the care burden73. The evidence base on 
caregiver burden in epilepsy is sparse in comparison with research in other, less prevalent, 
neurological conditions and even more so for caregivers supporting those with both epilepsy 
and ID74.  Albeit limited, the evidence indicates a substantial caregiver burden across 
multiple areas including physical, social and psychological domains75. 
Physically, parents report chronic fatigue and sleep deprivation as a consequence of 
their caring duties76. The responsibility of providing care for individuals with such complex 
needs is substantial, and even the most vigilant of families seem unable to prevent injuries 
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occurring; consequently, the pool of friends and extended family willing to provide respite 
care is diminished77. The social burden of care is evident in strained marital relationships, 
marginalisation of other siblings whose needs become overshadowed, and a restriction in 
social activities as families perceive their presence is unwanted or feared by others enjoying 
social occasions78,70. Psychologically, caregiving for those with complex needs is associated 
with impaired psychological health, emotional health, quality of life and well-being79. 
Behavioural difficulties provide an additional source of stress80. 
The ILAE has published a White Paper on the medical and social needs of people 
with epilepsy and ID71. The White Paper identifies the pivotal role of family caregivers and 
calls for recognition of their expertise and the promotion of shared care through greater 
knowledge transfer and communication with professionals. The White Paper also highlighted 
the need for more person centred approaches to consultations and the need for informed 
choice to be fostered among those with limited capacity.  The ILAE, as the leading 
professional association within the epilepsy field, is charged with highlighting the needs of 
both individuals and families, and with providing guidance to both epilepsy and ID services 
on how to optimally support families using practical solutions such as respite. 
 
Practice points for Social Policy standards 
1. Clinical services should recognize family burden and stress especially in families of people 
with behavioural disorder. 
2. Interagency collaboration is required between disability and epilepsy services – family 
members should be a key stakeholder in this collaboration. 
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3. Practical supports for families, such as respite and access to information, are urgently 
required. 
 
Conclusion 
Behaviour and its manifestations have a pervasive impact on people with an ID and epilepsy. 
Many areas of need are not provided by epilepsy services. Moreover, both epilepsy and 
intellectual disability vary by degree of severity, with few research papers exploring the 
impact of severity. Any child or adult with an ID, epilepsy and behavioural disorder should 
be provided with multi-disciplinary care to ensure quality of professional input and improved 
quality of life for the individual. A dearth of sound scientific evidence has been shown in 
several sections of this report. This is surprising and concerning after so many years of 
research.  
3-5 Key Bullet points: 
• Behaviour and its manifestations have a pervasive impact on people with intellectual 
disability and epilepsy. 
• A thorough assessment is required prior to pharmacological treatment as is close 
monitoring of side effects. 
• Clinical trial data for pharmacological and psychological interventions is limited for 
people with intellectual disability and epilepsy. 
• Intellectual disability is not a contraindication for epilepsy surgery, but the precise 
impact cannot be fully predicted. 
• Specific consideration is needed at times of transition (e.g. from child to adult 
services) and for family members. 
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Table 1: Clinical recommendations for the use of psychotropic medication for aggression 
Recommendation: Source: 
Except for acute aggressive emergency interventions, 
antipsychotics may be more harmful than helpful. 
(Tyrer et al. 200829; albeit 
contrasting results were 
reported by Gagiano30 et al 
2005). 
If necessary, atypical antipsychotics are recommended 
rather than traditional ones because of lower toxicity 
during long-term use.  
(Simon et al. 199631; Aman et 
al. 200432). 
Clozapine should be the last antipsychotic to be chosen 
because of its potential pro-convulsive nature, as well as 
unpredictable interactions with Carbamazepine and 
Valproate.  
(Alldredge 199933; Mula & 
Monach 200234; Mula et al. 
200435). 
While methylphenidate is considered to effectively control 
some behavioural problems arising from hyperactivity in 
paediatric patients with ID and/or epilepsy, relevant data 
on safety and efficacy are lacking in regard to adults with 
ID and epilepsy. 
(Simonoff et al. 201336; 
Baptista-Neto et al. 200837). 
Only consider antipsychotics when: 
Psychological or other interventions alone do not produce 
change within an agreed time or treatment for any 
coexisting mental or physical health problem has not led to 
a reduction in the behaviour or  the risk to the person or 
others is very severe (for example, because of violence, 
aggression or self-injury). 
(NICE 201538) 
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Only offer antipsychotic medication in combination with 
psychological or other interventions. 
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Table 2: Recommendations for adapting psychological therapy in people with ID56-57. 
Therapeutic element Definition 
Simplification  Less complex/technical; smaller chunks, shorter 
sessions 
Language  Reduce vocabulary/sentence structure and length of 
thought 
Activities  Augment typical activities; use of art, homework to 
make concepts concrete 
Developmental level  Integrate developmental level into presentation; use 
of games, relevant social contexts 
Directive methods Explicit outline of goals and progress 
Flexible methods Adjust usual methods to suit cognitive level and 
progress rate 
Involve caregivers Use family and support staff; help with homework 
Transference/countertransference Clear therapeutic boundaries; attachments can be 
stronger and take a parental role 
Sensitive interview methods Avoid response biases; agreeableness, suggestibility, 
confabulation 
Disability/rehabilitation approaches Address the disability; reflect issues relating to self-
identity and support positive self-review, mastery 
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Table 3: Psychological treatment studies of mental health problems in people with ID 57, 59. 
Population Intervention Effect 
Depression & ID 
3 studies 
1 treatment vs WL control60 
CBT 
CBT group 
therapy 
Reduced depression (behavior ratings and 
self-ratings) 
Decreased depression, negative thoughts, 
increased positive self-perceptions 
Anxiety & ID 
8 studies 
CBT, relaxation Reduced anxiety, improved cognitive 
performance 
Anger & ID 
6 studies 
CBT (anger 
management) 
Reduced anger and aggressive behaviours
Psychosis & ID 
3 studies 
Behavioural 
treatments 
Reduced displays of psychotic speech 
Offending & ID 
10 studies 
CBT Changes in attitudes towards offensive 
behaviour, reduced offending-related 
cognitions and offending 
ID 
92 studies50 
Psychotherapy Moderately beneficial effect across a 
range of outcome measures, primarily 
behaviour (79%) 
 
